256 related articles for article (PubMed ID: 33888468)
1. PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer.
Chabanon RM; Morel D; Eychenne T; Colmet-Daage L; Bajrami I; Dorvault N; Garrido M; Meisenberg C; Lamb A; Ngo C; Hopkins SR; Roumeliotis TI; Jouny S; Hénon C; Kawai-Kawachi A; Astier C; Konde A; Del Nery E; Massard C; Pettitt SJ; Margueron R; Choudhary JS; Almouzni G; Soria JC; Deutsch E; Downs JA; Lord CJ; Postel-Vinay S
Cancer Res; 2021 Jun; 81(11):2888-2902. PubMed ID: 33888468
[TBL] [Abstract][Full Text] [Related]
2. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
Chabanon RM; Muirhead G; Krastev DB; Adam J; Morel D; Garrido M; Lamb A; Hénon C; Dorvault N; Rouanne M; Marlow R; Bajrami I; Cardeñosa ML; Konde A; Besse B; Ashworth A; Pettitt SJ; Haider S; Marabelle A; Tutt AN; Soria JC; Lord CJ; Postel-Vinay S
J Clin Invest; 2019 Mar; 129(3):1211-1228. PubMed ID: 30589644
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ELF3 confers synthetic lethality of PARP inhibitor in non-small cell lung cancer.
Wang Y; Zuo M; Jin H; Lai M; Luo J; Cheng Z
J Recept Signal Transduct Res; 2021 Jun; 41(3):304-311. PubMed ID: 32814472
[TBL] [Abstract][Full Text] [Related]
4. PBRM1 Regulates the Expression of Genes Involved in Metabolism and Cell Adhesion in Renal Clear Cell Carcinoma.
Chowdhury B; Porter EG; Stewart JC; Ferreira CR; Schipma MJ; Dykhuizen EC
PLoS One; 2016; 11(4):e0153718. PubMed ID: 27100670
[TBL] [Abstract][Full Text] [Related]
5. MEK Inhibition Remodels the Immune Landscape of Mutant
Yang B; Li X; Fu Y; Guo E; Ye Y; Li F; Liu S; Xiao R; Liu C; Lu F; Huang J; Qin T; Han L; Peng G; Mills GB; Sun C; Chen G
Cancer Res; 2021 May; 81(10):2714-2729. PubMed ID: 33589518
[TBL] [Abstract][Full Text] [Related]
6. Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer.
Chang A; Liu L; Ashby JM; Wu D; Chen Y; O'Neill SS; Huang S; Wang J; Wang G; Cheng D; Tan X; Petty WJ; Pasche BC; Xiang R; Zhang W; Sun P
Cancer Res; 2021 Jun; 81(12):3358-3373. PubMed ID: 33853832
[TBL] [Abstract][Full Text] [Related]
7. The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.
Nargund AM; Pham CG; Dong Y; Wang PI; Osmangeyoglu HU; Xie Y; Aras O; Han S; Oyama T; Takeda S; Ray CE; Dong Z; Berge M; Hakimi AA; Monette S; Lekaye CL; Koutcher JA; Leslie CS; Creighton CJ; Weinhold N; Lee W; Tickoo SK; Wang Z; Cheng EH; Hsieh JJ
Cell Rep; 2017 Mar; 18(12):2893-2906. PubMed ID: 28329682
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma.
Gao W; Li W; Xiao T; Liu XS; Kaelin WG
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1027-1032. PubMed ID: 28082722
[TBL] [Abstract][Full Text] [Related]
9. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.
Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Parasramka M; Cheville JC; Wu KJ; Frenkel E; Rakheja D; Stefanius K; Brugarolas J; Parker AS
Urol Oncol; 2015 Jan; 33(1):23.e9-23.e14. PubMed ID: 25465300
[TBL] [Abstract][Full Text] [Related]
10. The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.
Hagiwara M; Fushimi A; Matsumoto K; Oya M
Eur Urol; 2022 Feb; 81(2):145-148. PubMed ID: 34627641
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis.
Yan X; Zhang X; Wang L; Zhang R; Pu X; Wu S; Li L; Tong P; Wang J; Meng QH; Jensen VB; Girard L; Minna JD; Roth JA; Swisher SG; Heymach JV; Fang B
Cancer Res; 2019 Jan; 79(1):125-132. PubMed ID: 30401714
[TBL] [Abstract][Full Text] [Related]
12. ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.
Shen J; Peng Y; Wei L; Zhang W; Yang L; Lan L; Kapoor P; Ju Z; Mo Q; Shih IeM; Uray IP; Wu X; Brown PH; Shen X; Mills GB; Peng G
Cancer Discov; 2015 Jul; 5(7):752-67. PubMed ID: 26069190
[TBL] [Abstract][Full Text] [Related]
13. A novel EZH2 inhibitor induces synthetic lethality and apoptosis in PBRM1-deficient cancer cells.
Huang K; Sun R; Chen J; Yang Q; Wang Y; Zhang Y; Xie K; Zhang T; Li R; Zhao Q; Zou L; Li J
Cell Cycle; 2020 Apr; 19(7):758-771. PubMed ID: 32093567
[TBL] [Abstract][Full Text] [Related]
14. THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors.
Shyamsunder P; Sridharan SP; Madan V; Dakle P; Zeya C; Kanojia D; Chng WJ; Ong ST; Koeffler HP
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163134
[TBL] [Abstract][Full Text] [Related]
15. CCL5-dependent mast cell infiltration into the tumor microenvironment in clear cell renal cell carcinoma patients.
Liu T; Xia Q; Zhang H; Wang Z; Yang W; Gu X; Hou T; Chen Y; Pei X; Zhu G; He D; Li L; Xu S
Aging (Albany NY); 2020 Nov; 12(21):21809-21836. PubMed ID: 33177244
[TBL] [Abstract][Full Text] [Related]
16. Combination Strategies for Immune Checkpoint Inhibitors in PBRM1-mutant Renal Cell Carcinoma: To PARP or Not To PARP?
Demidova EV; Ghatalia P; Arora S
Eur Urol; 2022 Feb; 81(2):149-150. PubMed ID: 34753637
[No Abstract] [Full Text] [Related]
17. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.
Liu XD; Kong W; Peterson CB; McGrail DJ; Hoang A; Zhang X; Lam T; Pilie PG; Zhu H; Beckermann KE; Haake SM; Isgandrova S; Martinez-Moczygemba M; Sahni N; Tannir NM; Lin SY; Rathmell WK; Jonasch E
Nat Commun; 2020 May; 11(1):2135. PubMed ID: 32358509
[TBL] [Abstract][Full Text] [Related]
18. PBRM1 bromodomains variably influence nucleosome interactions and cellular function.
Slaughter MJ; Shanle EK; McFadden AW; Hollis ES; Suttle LE; Strahl BD; Davis IJ
J Biol Chem; 2018 Aug; 293(35):13592-13603. PubMed ID: 29986887
[TBL] [Abstract][Full Text] [Related]
19. Roles of DNA damage repair and precise targeted therapy in renal cancer (Review).
Lai Y; Li Z; Lu Z; Zheng H; Chen C; Liu C; Yang Y; Tang F; He Z
Oncol Rep; 2022 Dec; 48(6):. PubMed ID: 36263616
[TBL] [Abstract][Full Text] [Related]
20. BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency.
Gupta M; Concepcion CP; Fahey CG; Keshishian H; Bhutkar A; Brainson CF; Sanchez-Rivera FJ; Pessina P; Kim JY; Simoneau A; Paschini M; Beytagh MC; Stanclift CR; Schenone M; Mani DR; Li C; Oh A; Li F; Hu H; Karatza A; Bronson RT; Shaw AT; Hata AN; Wong KK; Zou L; Carr SA; Jacks T; Kim CF
Cancer Res; 2020 Sep; 80(18):3841-3854. PubMed ID: 32690724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
